Adenosine A₃ receptor as a novel therapeutic target to reduce secondary events and improve neurocognitive functions following traumatic brain injury.

ABSTRACT:

Background

Traumatic brain injury (TBI) is a common pathological condition that presently lacks a specific pharmacological treatment. Adenosine levels rise following TBI, which is thought to be neuroprotective against secondary brain injury. Evidence from stroke and inflammatory disease models suggests that adenosine signaling through the G protein-coupled A₃ adenosine receptor (A₃AR) can provide antiinflammatory and neuroprotective effects. However, the role of A₃AR in TBI has not been investigated.

Methods

Using the selective A₃AR agonist, MRS5980, we evaluated the effects of A₃AR activation on the pathological outcomes and cognitive function in CD1 male mouse models of TBI.

Results

When measured 24 h after cont

SUBMITTER: Farr SA 

PROVIDER: S-EPMC7659122 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature